72.6 F
New York
Monday, May 17, 2021

Trevena [NASDAQ: TRVN] Soar on Selection of TRV027in Global COVID-19 Trial

Must read

Oaktree [NASDAQ: OCSL] Announces Pricing of Underwritten Public Offering

Oaktree Specialty Lending Corporation disclosed that it has set the price of an underwritten public offering of $350.0 million aggregate principal amount of...

Black.one Introduces Cryptocurrency Exchange Venture with $10B in Funding

Black.one has disclosed Tuesday that it has launched Bullish Global. Bullish Global is a subsidiary of Black.one. It is a new blockchain-based cryptocurrency exchange...

Pfizer-BioNTech COVID-19 Vaccine Gets FA Approval for Emergency Use in Adolescents

Pfizer Inc. and BioNTech SE disclosed that its COVID-19 vaccine has got the FDA approval for its COVID-19 vaccine. After the approval,...

Soliton [NASDAQ: SOLY] to be Acquired by Allergan Aesthetics

Soliton, Inc. disclosed Monday that it has inked an agreement with Allergen Aesthetics. As per the agreement, Allergen Aesthetics will buy Soliton. Allergen...

Shares of Trevena, Inc. [NASDAQ: TRVN] skyrocketed more than 5 percent during the pre-market trading session of Wednesday. The strong performance of the firm indicated the positive reaction of its investors after it disclosed the positive news regarding TRV027.

Trevena disclosed that TRV027 has been chosen for addition in a worldwide, multi-site, adaptive, Phase II-Phase III study in COVID-19 sufferers. The study has been carried out and financed as part of REMAP-CAP. The main objective of the study is to assess cure with the ability to decrease mortality, ICU admission, and morbidity in critically sick sufferers with COVID-19.

Details of REMAP-CAP COVID-19 ACE2 RAS Modulation Domain

The study has introduced as “REMAP-CAP COVID-19 ACE2 RAS Modulation Domain”. Moreover, TRV027 is developed on Nobel Prize-winning technology. This is the greatest accomplishment of the firm. It will allow the firm to bring a new cure for the sufferers living with COVID-19 infection.

Earlier, it has been revealed that Imperial College London has been examined as an evidence-based study. Moreover, the recent findings of the Data Monitoring and Safety Committee (DMSC) also encourage the use of TRV027.

DMSC discovered that there were no safety concerns related to TRV027. Imperial College London contemplates covering its research in the near future. Furthermore, it is also encouraging the development of TRV027 into the REMAP-CAP COVID-19 RAS domain study.

More articles

Latest article

Elon Musk’s SpaceX to Roll Out Dogecoin-Backed Satellite to the Moon in 2022

Elon Musk’s SpaceX has decided to recognize Dogecoin as payment to roll out its “DOGE-1 Mission to the Moon”. The mission is going to...

SBI CEO Yoshitaka Kitao Reveals Ripple to Go Public after its Legal Battle with the SEC is Over

CEO of Japanese financial services company SBI Holdings, Yoshitaka Kitao disclosed that Ripple has opted for an option to go public once its legal...

Coinbase Pro Announces it will be Listing Internet Computer’s ICP

Coinbase Pro cryptocurrency exchange has disclosed that it has decided to list ICP once it goes live. ICP is the governance token of the...

WISeKey [NASDAQ: WKEY] Gets Investment to finance its TrustNFT.IO NFT Platform

WISeKey International Holding AG disclosed Friday that it has inked a term-sheet to enter into an unsecured short-term loan and the issuance and...

Moderna [NASDAQ: MRNA] Inks Supply Agreement with Switzerland

Moderna, Inc. disclosed that it has inked a supply agreement on Thursday with the Swiss Federal Government. As per the agreement, Moderna Inc...

TeraBlock Will Have its Own BSCPad IDO Soon

TeraBlock which is a project making a platform for automated cryptocurrency portfolio management disclosed that it is preparing for an initial DEX offering (IDO)...

Why Chiasma [NASDAQ: CHMA] Stock is Skyrocketed?

Shares of Chiasma, Inc. surged 46.48% during the trading session of Wednesday. Chiasma has disclosed the financial results for the Q1 completed March...

NeoGenomics [NASDAQ: NEO] Announces Acquisition of Inivata Ltd

NeoGenomics, Inc. revealed Wednesday that it has decided to purchase Inivata Ltd. Inivata will grow into a liquid biopsy-centered division together with increasing...